MCC950

Catalog No.S8930 Batch:S893001

Technical Data

Formula

C₂₀H₂₄N₂O₅S

Molecular Weight

404.48

CAS No.

210826-40-7

Solubility (25°C)*

In vitro

DMSO

81 mg/mL (200.25 mM)

Ethanol

3 mg/mL (7.41 mM)

Water

Insoluble

In Vivo (Add solvents to the product individually and in order.)

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

MCC950 (CP-456773, CRID3) is a potent and selective inhibitor of NLRP3 (NOD-like receptor (NLR) family, pyrin domain-containing protein 3) with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively.

Targets

NLRP3 (BMDM-based assay)	NLRP3 (HMDM-based assay)
7.5 nM	8.1 nM

In vitro

MCC950 specifically inhibits NLPR3 inflammasome activation.

In Vivo

Inhibition of NLRP3 with MCC950 ameliorates proteinuria, renal histological lesions and podocyte foot process effacement in lupus-prone mice.

Protocol (from reference)

Cell Assay:^{^[1]}	Cell Lines NZM2328 podocyte cell line Concentrations 1 µM Incubation Time 24 h Method The NZM2328 podocyte cell line was stimulated with a control serum or a serum from diseased NZM2328 mice or serum from diseased NZM2328 mice depleted of IgG, with or without MCC950 or Mito TEMPO for 24 hours. After this incubation, cells were subjected to flow cytometry and Western blot analyses for NLRP3 inflammasome activation, mitochondrial membrane potential and production of reactive oxygen species (ROS) analysis. (Data sourced from selleck products)
Animal Study:^{^[1]}	Animal Models female NZM2328, a new NZM strain produced by extended backcrosses of NZB/WF1 to NZW mice Dosages 10mg/kg Administration i.p. (Data sourced from selleck products)

Cell Assay:^{^[1]}

Cell Lines
NZM2328 podocyte cell line
Concentrations
1 µM
Incubation Time
24 h
Method
The NZM2328 podocyte cell line was stimulated with a control serum or a serum from diseased NZM2328 mice or serum from diseased NZM2328 mice depleted of IgG, with or without MCC950 or Mito TEMPO for 24 hours. After this incubation, cells were subjected to flow cytometry and Western blot analyses for NLRP3 inflammasome activation, mitochondrial membrane potential and production of reactive oxygen species (ROS) analysis.

(Data sourced from selleck products)

Animal Study:^{^[1]}

Animal Models
female NZM2328, a new NZM strain produced by extended backcrosses of NZB/WF1 to NZW mice
Dosages
10mg/kg
Administration
i.p.

(Data sourced from selleck products)

References

https://pubmed.ncbi.nlm.nih.gov/28544564/
https://pubmed.ncbi.nlm.nih.gov/35294888/
https://pubmed.ncbi.nlm.nih.gov/36087465/

Sellecks MCC950 Has Been Cited by 147 Publications

Exosomal transfer of pro-pyroptotic miR-216a-5p exacerbates anthracycline cardiotoxicity through breast cancer-heart pathological crosstalk [ Signal Transduct Target Ther, 2025, 10(1):157]	PubMed: 40360476
Human heart-macrophage assembloids mimic immune-cardiac interactions and enable arrhythmia disease modeling [ Cell Stem Cell, 2025, 32(11):1671-1690.e13]	PubMed: 41151577
Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action [ J Exp Med, 2025, 222(11)e20242403]	PubMed: 40892070
The inflammasome sensor NLRP3 interacts with REV7 to maintain genome integrity through homologous recombination [ Nucleic Acids Res, 2025, 53(12)gkaf554]	PubMed: 40613708
PM2.5 exacerbates nasal epithelial barrier dysfunction in allergic rhinitis by inducing NLRP3-mediated pyroptosis via the AhR/CYP1A1/ROS axis [ J Hazard Mater, 2025, 492:138145]	PubMed: 40209413
Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity [ J Immunother Cancer, 2025, 13(10)e012182]	PubMed: 41052880
Monocyte membrane-coated drug nanocrystals for enhanced targeted therapy of rheumatoid arthritis [ J Control Release, 2025, 384:113919]	PubMed: 40460929
Resibufogenin protects against atherosclerosis in ApoE-/- mice through blocking NLRP3 inflammasome assembly [ J Adv Res, 2025, S2090-1232(25)00272-3]	PubMed: 40258472
LL37 complexed to double-stranded RNA induces RIG-I-like receptor signalling and Gasdermin E activation facilitating IL-36γ release from keratinocytes [ Cell Death Dis, 2025, 16(1):198]	PubMed: 40121229
A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity [ Cell Death Dis, 2025, 16(1):252]	PubMed: 40185713

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.